[1]Philippi, Z., et al., Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions. Int J Mol Sci, 2025. 26(13).
[2]Llovet, J.M., et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008. 359(4): p. 378-90.
[3]Llovet, J.M., et al., Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021. 73 Suppl 1: p. 158-191.
[4]Finn, R.S., et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020. 382(20): p. 1894-1905.
[5]Pinter, M. and W. Sieghart, Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? memo – Magazine of European Medical Oncology, 2018. 11(3): p. 185-192.
[6]Dong, J., et al., LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC). Annals of Oncology, 2025. 36: p. S62.
[7]Huang, Z., et al., Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study. Int Immunopharmacol, 2024. 139: p. 112711.
[8]Sun, H.C., et al., 1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial. Annals of Oncology, 2025. 36: p. S885.
[9]国际肝胆胰协会中国分会肝胆胰Mdt专业委员会 中华医学会外科学分会肝脏外科学组 中国老年医学学会普外科分会, 中.编., 张必翔, and 钦伦秀, 肝细胞癌围手术期免疫治疗多学科协作专家共识（2025版）. 中华消化外科杂志, 2025. 24(6): p. 678-689.
[10]Liao, Y., W. Zhu, and J. Zhang, Efficacy and safety of TACE/HAIC combined with targeted immunotherapy versus targeted immunotherapy for advanced hepatocellular carcinoma: a meta-analysis. Front Oncol, 2025. 15: p. 1669460.
[11]Chen, X., et al., Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma. Cancer Immunol Immunother, 2025. 74(11): p. 331.
[12]Yu, X., et al., Efficacy and safety of atezolizumab combined with bevacizumab, arterial chemoembolization, and hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma: a meta-analysis. Int J Clin Exp Pathol, 2024. 17(12): p. 444-457.
[13]Federico, P., et al., How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel), 2021. 14(3).
[14]Mok, K., et al., Systemic therapy for child-pugh B patients with hepatocellular carcinoma. Expert Opin Emerg Drugs, 2025.
[15]王伟, 刘., 肝癌多学科诊疗体系的建立及其评价. 中国实用外科杂志, 2024. 44(09): p. 1001-1005.
